EASL™ Congress 2023 06/21 - 06/24/23 Supporting Materials Safety and efficacy of VIR-2218 with or without pegylated interferon alfa in virally-suppressed participants with chronic hepatitis B virus infection: Post-treatment follow-up (Late-Breaker Oral) 909.1 KB Safety and antiviral activity of short-duration combinations of the investigational siRNA VIR-2218 with the neutralizing, vaccinal monoclonal antibody VIR-3434: post-treatment follow-up from the Phase 2 MARCH trial (Oral) 1.2 MB VIR-2218 and VIR-3434 therapy is efficacious in preclinical models of Hepatitis Delta Virus infection (Poster) 1 MB Single dose pharmacokinetics of VIR-3434, a novel neutralizing monoclonal antibody, in participants with chronic hepatitis B virus infection (Poster) 577.2 KB Treatment eligibility and initiation among chronic hepatitis B patients in a real-world setting in the United States (Poster) 3.4 MB
Safety and efficacy of VIR-2218 with or without pegylated interferon alfa in virally-suppressed participants with chronic hepatitis B virus infection: Post-treatment follow-up (Late-Breaker Oral) 909.1 KB
Safety and antiviral activity of short-duration combinations of the investigational siRNA VIR-2218 with the neutralizing, vaccinal monoclonal antibody VIR-3434: post-treatment follow-up from the Phase 2 MARCH trial (Oral) 1.2 MB
VIR-2218 and VIR-3434 therapy is efficacious in preclinical models of Hepatitis Delta Virus infection (Poster) 1 MB
Single dose pharmacokinetics of VIR-3434, a novel neutralizing monoclonal antibody, in participants with chronic hepatitis B virus infection (Poster) 577.2 KB
Treatment eligibility and initiation among chronic hepatitis B patients in a real-world setting in the United States (Poster) 3.4 MB
